jhc2026v10i2


Editorial
1. ASCO 2026 Guideline: Rethinking PD-L1 Testing
Rahman DA
Original Contributions
2.Lupus Nephritis; an Unrevealed Morbidity in Bangladeshi Population- A Clinical and Histomorphological Study
Imrana, Islam SJ, Rahman TS, Azad A
3.Stromal Expression of CD10 in Oral Squamous Cell Carcinoma and its Association with Histological Grade
Hasnain M, Jeba R, Doly NJ, Hasan M, Nahar R, Nupur FP
4.Spectrum of Hepatic Lesions Diagnosed by Image-Guided Cytology and Core Needle Biopsy: A Retrospective Clinicopathological Study
Quruni MO, Hossain MS, Afrin SS, Saha MK, Alam SN, Nupur FP, Jahan PA
5.Immunohistochemical Expression of Extracellular Matrix Metalloproteinase Inducer (EMMPRIN/CD147) in Renal Cell Carcinoma and Its Association with Histological Grade and Pathological Stage
Mahmud S, Bhuiyan AZ,Hossain SA, Yasmin R,Saha MK,Masud MR,Shakila J, Afrin S
6.Histomorphological Pattern of Sellar and Suprasellar Region Tumor in Tertiary Level Hospital of Bangladesh
Shirin S, Jeba R, Wahid SR, Nupur FP, Jannat MR
7.Vimentin Expression in Renal Cell Carcinoma and It’s Association with Histological Grade and Pathological Stage
Adhikary P, Begum S, Ferdous JN, Saha AK, Papry A, Emita U
8.Vimentin Expression in Infiltrating Ductal Carcinoma NOS of Breast and its Association with Clinicopathological Characteristics
Tahsin KN, Doly NJ, Rashid HO,Yeamin MA, Sultana S,Khan RR, Jeba R
9.Immunohistochemical Evaluation of PD-L1 Expression in Triple-Negative Breast Cancer: An Analysis of 83 Cases
Alam MM, Dey BP, Akhtaruzzaman M, Jahan I, Nahid MS, Rahman MZ
10.PD-L1 Immunoexpression in Selected Cases of Lung Carcinoma: A Retrospective Cross-Sectional Study from a Tertiary Care Center in Bangladesh
Khanam KF, Ayeeda AS, Omar T, Bhuiyan MT, Khanam KA, Bhadra S,Manik MM
Case Reports
11.Heterotopic Ossification of the Gallbladder Associated with Chronic Cholecystitis: A Case Report
Anjum R, Hossain GZ
12.Pulmonary Sclerosing Pneumocytoma: Diagnostic Challenges in Frozen Section – A Case Report and Literature Review
Anjum R, Hossain Bhuiyan MZ
13.BRAF V600E-Positive Classical Papillary Thyroid Carcinoma: Integrating Histopathological Diagnosis with Next-Generation Sequencing for Personalized Oncological Management – A Case Report
Rahman DA, Akter S
14. Eosinophilic Mastitis: A Rare Case Report
Hussain AR, *Khanam KF, Akhter S, Omar T, Ayeeda AS,  Khanam KA

Information for Contributors

Front Cover PDF

Content/index PDF

Inside Back cover PDF

Editorial Board PDF

jhc.2026.10.1.10

Journal of Histopathology and Cytopathology
Vol 10. Issue 1, 2026

Uniform Criteria for Submission of Manuscript to the Editorial Board

[According to Guideline of BMDC]

  1. Manuscript written in English on bio medical topics will be considered for publication provided these have not been published previously and are not under consideration for publication elsewhere.
  2. The author should obtain written permission from appropriate authority if the manuscript contains any table, data or illustration from previously published in other Journal. The letter of permission should be submitted with manuscript to the editorial board.
  3. Authors should keep one copy of their manuscript for reference & three hard copies along with softcopy should be sent to the managing editor.
  4. The authors should sign a covering letter mentioning that final manuscript has been seen and approved by all authors. Relevancy and contribution of coauthors should clearly mentioned by first author. Irrelevant person or without any contribution should not be entitled as coauthors.
  5. The materials submitted for publication may be in the form of an original research, review article, special article, a case report, recent advances, new techniques, books review on clinical / medical education, adverse drug reaction or a letter to the editor.
  6. An author can write review article only if he / she has written a minimum of two (2) original research articles and four (4) case reports on the same topic.
  7. The manuscript may be submitted by the author online following appropriate criteria as mentioned.
  8. Each component of the manuscript should begin on a new page in the sequence of-
  • Title page
  • Abstract
  • Text- Introduction, Material & Methods, Result and Discussion.
  • References
  • Acknowledgement
  1. The title page should include the title of the paper, name of the authors, name of the departments in which they worked, email address & phone number.
  2. The title should be concise, informative & self explanatory.
  3. The Abstract should be structured as-introduction with objectives, materials & methods, result, discussion with conclusion including key words number of figures, tables, reference & correspondence
  4. The text should be presented in the form of-
  • Introduction: This should include the purpose of the article. The rational for the study or observation should be summaries. Only strictly pertinent reference should be cited. The subject should not be extensively reviewed. Data or conclusion from the work being reported should not be presented in introduction.
  • Materials & methods: study design & sampling method should be mentioned. Consent from respondents / patients should be taken in the form before interview / study. All drugs & chemicals used should be identified precisely, including generic name, dose route of administration. For all quantitative measurement SI unit should be used.
  • Results: This should be presented in a logical sequence in the text, tables & illustration. For Statistical Analysis standard procedure to be maintained. It should be done by a recognized statistician or subject expert related to statistics.
  • Discussion: Authors comment on the result supported with contemporary references including arguments and analysis of identical work done by other workers may be elaborately discussed. A summary is not required. Brief acknowledgement may be made at the end.
  • Tables: Number and titles of tables to be clearly written.
  • Source of Illustrations & Figures should be mentioned.
  • Abbreviations and Symbols: Use only standard abbreviations; avoid abbreviations in the title of the article.
  1. References-
  • Reference should be numbered in order to which they appear in the text as superscript.
  • Reference should be in Vancouver style

*Authors are requested to send manuscript of article via email attached MS Word file.

Email: sadequel@yahoo.com

Open in PDF

jhc.2026.10.1.9

Journal of Histopathology and Cytopathology
Vol 10, Issue 1, 2026

Comparative Analysis of Serum β-hCG Levels in Complete and Partial Hydatidiform Moles
 Rahman MM,1 Kabir AN,2 Islam T,3 Shiraj-Um-Mahmuda S,4 Karim R,5 *Shabnam US6

Abstract
Introduction: Hydatidiform mole (HM) is a gestational trophoblastic disorder caused by abnormal fertilization, resulting in a non-viable pregnancy with trophoblastic hyperplasia. Differentiation between complete hydatidiform mole (CHM) and partial hydatidiform mole (PHM) is clinically important because CHM carries a higher risk of persistent trophoblastic disease. Serum β-hCG is often markedly elevated in molar pregnancy and may assist in distinguishing CHM from PHM. This study aimed to evaluate pretreatment β-hCG levels among different types of hydatidiform mole and assess their diagnostic association.
Methods: This cross-sectional study included 57 histopathologically diagnosed cases of HM collected from the BMU and private laboratories in Dhaka. Pretreatment serum β-hCG levels were obtained for all patients. Based on histopathological criteria, cases were grouped into CHM, PHM, and indeterminate categories. Statistical analysis using Mann-Whitney and Kruskal-Wallis tests was performed to compare β-hCG levels between groups.
Results: Of the 57 cases, 36 were CHM, 13 were PHM, and 8 were categorized as indeterminate. Serum β-hCG levels showed statistically significant variation among the three groups, with CHM showing markedly higher levels than PHM. Elevated β-hCG demonstrated a strong association with the histopathological diagnosis of HM.
Conclusion: Pretreatment serum β-hCG level is a valuable adjunct in differentiating complete from partial hydatidiform mole. When used alongside histopathological assessment, β-hCG can enhance diagnostic confidence and guide appropriate clinical management.

[Journal of Histopathology and Cytopathology, 2026 Jan; 10 (1):71-83]
DOI: https://www.doi.org/10.69950/jhc.2026.10.1.9

Keywords: β-hCG, complete hydatidiform mole, partial hydatidiform mole, trophoblastic disease.

  1. Dr. Mohammad Mosiur Rahman, Associate Professor, Patholog), Bangladesh Medical University, Bangladesh. mosiurpath@bsmmu.edu.bd.
  2. Dr. AKM Nurul Kabir, Professor, Pathology, Bangladesh Medical University, Dhaka
  3. Dr. Tasmia Islam, Assistant Professor, Pathology, Bangladesh Medical University. Dhaka
  4. Dr. Syeeda Shiraj-Um-Mahmuda, MD (Pathology), OSD, Directorate General of Health Services (DGHS).
  5. Dr. Rezwana Karim, Associate Professor (C.C), Pathology, US – Bangla Medical College and Hospital, Dhaka
  6. *Dr. Ummey Salma Shabnam, Assistant Professor (Histopathology), National Institute of Cancer Research and Hospital, Place. salmamithun@gmail.com. Orcid id: 0009-0005-1751-116X,

*For correspondence

Open full Article as PDF